Exploring novel therapeutics alongside further research into the specific targeting of NLRP3 inflammasome components will undeniably offer hope for treating NLRP3-inflammasome associated diseases, such as diabetic nephropathy (Kim et al., 2015; Sha et al., 2017; Mugisho et al., 2018; International Diabetes Federation, 2019; Zhao et al., 2019; Sun et al., 2020; Wang et al., 2020; Al Mamun et al., 2021; Samsu, 2021; ClinicalTrials.gov, 2022). Here, NLRP3 is linked to diabetic kidney disease.